Emvistegrast Phase 2 Success: Bold Oral Colitis Data
Emvistegrast Phase 2 results: Gilead’s oral pill met the SWIFT primary endpoint in ulcerative colitis, 66% vs 37% on placebo. Not yet approved.
Emvistegrast Phase 2 results: Gilead’s oral pill met the SWIFT primary endpoint in ulcerative colitis, 66% vs 37% on placebo. Not yet approved.